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Introduction
Peptic ulcer disease (PUD) is a common condition, lead-
ing to incident hospital contact in 2 per 1000 persons 
annually [1]. Helicobacter pylori (H. pylori) colonizes both 
duodenal ulcers (approximately 80% [2]) and to a lesser 
degree gastric ulcers (approximately 50% [3]), and has 
been associated with increased risk of gastric cancer [4, 
5]. H. pylori also has been detected in nongastric gas-
trointestinal (GI) tissue, though this may reflect natural 
excretions rather than tissue colonization [6]. Therefore, 
there is growing interest in a possible link between H. 
pylori infection, peptic ulcer, and risk of nongastric GI 
cancers [7–9]. In addition, several lifestyle factors are 
associated with an increased risk of PUD and also affect 
cancer risk. Aspirin and other nonsteroidal anti- 
inflammatory drugs (NSAIDs) increase PUD risk, par-
ticularly gastric ulcers [10], but may lower the risk of 
gastric and colorectal cancer [11–13]. Tobacco smoking 
is an important risk factor for PUD [10] and is 
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Abstract
Peptic ulcer predicts gastric cancer. It is controversial if peptic ulcers predict 
other gastrointestinal cancers, potentially related to Helicobacter pylori or shared 
lifestyle factors. We hypothesized that gastric and duodenal ulcers may have 
different impact on the risk of gastrointestinal cancers. In a nationwide cohort 
study using Danish medical databases 1994–2013, we quantified the risk of 
gastric and other gastrointestinal cancers among patients with duodenal ulcers 
(dominantly H. pylori- related) and gastric ulcers (dominantly lifestyle- related) 
compared with the general population. We started follow- up 1- year after ulcer 
diagnosis to avoid detection bias and calculated absolute risks of cancer and 
standardized incidence ratios (SIRs). We identified 54,565 patients with gastric 
ulcers and 38,576 patients with duodenal ulcers. Patient characteristics were 
similar in the two cohorts. The 1–5- year risk of any gastrointestinal cancer was 
slightly higher for gastric ulcers patients (2.1%) than for duodenal ulcers patients 
(2.0%), and SIRs were 1.38 (95% CI: 1.31–1.44) and 1.30 (95% CI: 1.23–1.37), 
respectively. The SIR of gastric cancer was higher among patients with gastric 
ulcer than duodenal ulcer (1.92 vs. 1.38), while the SIRs for other gastrointes-
tinal cancers were similar (1.33 vs. 1.29). Compared with gastric ulcer patients, 
duodenal ulcer patients were at lower risk of smoking- and alcohol- related 
gastrointestinal cancers. The risk of nongastric gastrointestinal cancers is increased 
both for patients with gastric ulcers and with duodenal ulcers, but absolute 
risks are low. H. pylori may be less important for the development of nongastric 
gastrointestinal cancer than hypothesized. 
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associated with the development of several GI cancers 
[14]. Finally, alcohol overuse may increase risk of PUD, 
as indicated by the strong association between liver cir-
rhosis and pancreatic disease and increased PUD incidence 
[15]. Alcohol overuse is similarly associated with several 
GI cancers [10, 14].
While H. pylori is highly prevalent among duodenal 
ulcer patients, use of NSAIDs, smoking, and alcohol- related 
disease may be particularly frequent among gastric ulcer 
patients [15–17]. Because of these possible differences, we 
hypothesized that gastric and duodenal ulcers may have 
different impact on the risk of GI cancers. We assessed 
absolute risks of gastric and other GI cancers among 
gastric and duodenal ulcer patients identified in Danish 
medical registries. We then compared their cancer risk 
with that in the general Danish population.
Materials and Methods
Data sources and study population
This registry- based cohort study was based on the cumu-
lative Danish population of approximately 7 million persons 
during the 1994–2013 period. The Danish National Health 
Service provides tax- funded medical care to all Danish 
residents and guarantees free access to hospitals and out-
patient clinics [18]. The unique identifier assigned to every 
Danish resident allows linkage among Danish registries 
[19]. We identified gastric and duodenal ulcer patients 
from the Danish National Patient Registry (DNPR), which 
has recorded all admissions to Danish hospitals since 1977 
and all outpatient clinic visits since 1994. Diagnoses are 
classified according to the International Classification of 
Diseases (ICD), 8th revision (ICD- 8) until the end of 
1993 and 10th revision (ICD- 10) thereafter [20]. The main 
reason for diagnostic work- up and treatment during a 
hospital contact is registered in the DNPR as the primary 
diagnosis, whereas other acute and chronic diseases or 
conditions are recorded as secondary diagnoses. We identi-
fied all patients with a first- time hospital diagnosis (inpa-
tient diagnosis or hospital outpatient clinic visit diagnosis) 
of gastric ulcer or duodenal ulcer during the period January 
1994 to November 2013. We obtained information on 
reimbursed medications redeemed at Danish community 
and outpatient pharmacies from the Danish National 
Health Service Prescription Database (DNDRP), established 
in 2004 [21]. We obtained data on cancer diagnoses, clas-
sified according to ICD–10, from the Danish Cancer 
Registry (DCR), which has recorded incident cancers in 
Denmark since 1943 [22].
All ICD- codes and Anatomical Therapeutic Chemical 
(ATC) classification system codes used in this study are 
provided as online material (Appendix A1).
Cancer
We linked all members of our study cohorts to the 
DCR to identify incident GI cancer cases (using ICD–10 
codes). We excluded patients diagnosed with cancer 
(expect for non–melanoma skin cancer) before the date 
of PUD diagnosis. We then excluded cancers occurring 
during the first year of follow- up to minimize inclusion 
of ulcers detected during diagnostic work- up for cancer, 
as well as to exclude cancers detected in patients for 
whom an ulcer prompted further diagnostic work- up. 
We examined the occurrence of the following GI cancers 
one or more years after PUD: oral and pharyngeal, 
esophageal, gastric, small intestinal, colon, rectal, anal, 
pancreatic, liver, and gallbladder and biliary tract. We 
considered oro- pharyngeal, esophageal, gastric, colorectal, 
pancreatic, and liver cancers as tobacco- and alcohol- 
related cancers [10, 14].
Covariates
To characterize patients and address the potential for 
confounding and effect modification, we obtained infor-
mation on coexisting diseases, proxy measures of lifestyle 
factors, and medication use before the hospital contact 
for ulcers. From the DNPR, we obtained information on 
chronic pulmonary disease (as a proxy for smoking), 
alcoholism- related conditions (as a proxy for excess alcohol 
intake), severe liver disease, diabetes, obesity, and car-
diovascular disease diagnosed at any time prior to or 
during the hospital contact for ulcer disease. We also 
obtained information on gastroscopies and lower endos-
copies performed during the hospital contact for ulcer 
disease.
From the DNDRP, we obtained information on use 
(yes/no) of NSAIDs (including low- and high- dose aspi-
rin, selective cyclooxygenase- 2 inhibitors, and other 
NSAIDs); proton- pump inhibitors (PPIs) and histamine 
H2- receptor antagonists (H2- blockers); and H. pylori- 
eradication therapy (the combination of amoxicillin, 
clarithromycin, and metronidazole) in the year preceding 
the ulcer diagnosis. Information on drug use was avail-
able for patients diagnosed with PUD during 2005–2013, 
allowing 1 year time window of medication use for all 
patients.
Statistical analysis
We followed each patient for occurrence of cancer starting 
1 year after first hospital contact with a gastric or duo-
denal ulcer diagnosis until the date of death, emigration, 
or 30 November 2013, whichever came first. We computed 
distributions and frequencies of gender, age categories 
1343© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
Peptic Ulcer and Long- Term Cancer RiskK. K. Søgaard et al.
(≤39, 40–64, 65+), and the covariates. Median follow- up 
(interquartile range, IQR) and median age (IQR) at inclu-
sion were calculated.
We computed 1–5- year absolute risks of cancer in patients 
with PUD, considering death as a competing risk [23], 
and censoring patients at the end of the study period. 
We used standardized incidence ratios (SIRs) as a measure 
of relative risks to compare the observed cancer incidence 
among patients with PUD with that expected in the entire 
Danish population [24]. The expected number of cancer 
cases was estimated based on national cancer incidence 
rates by age (5- year age groups), sex, and calendar year 
(5- year periods). Confidence intervals (95% CIs) for SIRs 
were calculated assuming that the observed number of 
cancers followed a Poisson distribution, using Byar’s 
approximation [25]. We calculated SIRs for all GI cancers 
combined and individually and stratified by patient 
characteristics.
Because we were interested in detecting possible differ-
ences in characteristics and cancer risks between patients 
with gastric versus duodenal ulcers, all analyses were per-
formed according to ulcer site. In a secondary analysis, 
we compared the observed cancer incidence among duo-
denal ulcer patients directly to that found among gastric 
ulcer patients (standardized on age, gender, and calendar 
year) [24].
All statistical analyses were conducted using the SAS 
statistical software package, v. 9.2 (SAS Institute, Cary, 
NC). The study was approved by Danish Data Protection 
Board (record number 1- 16–02–1–08 and 2012–41–0793). 
Danish registry data are generally available for research 
purposes and, according to Danish law, use of the data 
do not require informed consent.
Results
We identified 119,212 patients with a first gastric or duo-
denal ulcer diagnosis between 1994 and 2013. Among all 
patients the 1- year absolute risk of cancer was 2.3%. We 
then excluded 5672 patients diagnosed with cancer within 
the first year after ulcer diagnosis (oral and pharyngeal 
cancer: 84 cases; esophageal cancer: 106 cases; gastric cancer: 
926 cases; small intestinal cancer: 100 cases; colon cancer: 
676 cases, rectal cancer: 132 cases; anal cancer: 8 cases; 
pancreatic cancer: 404 cases; liver cancer: 144 cases; gall-
bladder or biliary tract cancer: 89 cases; other cancers: 
3003 cases) and 20,399 patients with less than 1 year of 
follow- up, yielding a total of 93,141 persons with a hospital- 
based gastric or duodenal ulcer diagnosis. Among patients 
diagnosed with GI cancer in the first year of follow- up, 
the prevalence of gastroscopy performed during the ulcer- 
related hospital contact was 75% and the corresponding 
prevalence of lower endoscopy was 12%.
Patient characteristics
Our final cohort of 93,141 peptic ulcer disease patients 
included 54,565 (59%) with a first gastric ulcer diag-
nosis and 38,576 (41%) with a first duodenal ulcer 
diagnosis. Patients with gastric ulcer were slightly older 
than patients with duodenal ulcer (median ages: 65 years 
vs. 63 years). After a 1–year induction period, patients 
with gastric ulcers and duodenal ulcers were followed 
for a median of 5 and 6 years, respectively. Most 
patients were diagnosed with an ulcer during an inpa-
tient admission, the ulcer was the main reason for 
admission, and the diagnosis was gastroscopically con-
firmed (Table 1). Patients with gastric and duodenal 
Table 1. Characteristics of patients with gastric ulcer (n = 54,565) and 
duodenal ulcer (n = 38,576), Denmark, 1994–2013.
Gastric ulcer, 
n (%)
Duodenal ulcer, 
n (%)
Women 29,372 (54) 16,755 (43)
Median age, years (IQR) 65 (52–77) 63 (49–76)
Median follow- up, years (IQR) 5 (2–10) 6 (3–12)
Calendar period
1994–1998 16,730 (31) 13,954 (36)
1999–2003 14,723 (27) 11,384 (30)
2004–2008 13,550 (25) 8323 (21)
2009–2013 9562 (17) 4915 (13)
Type of ulcer diagnosis
Primary 43,544 (80) 32,554 (84)
Secondary 11,021 (20) 6022 (16)
Type of admission
Inpatient 36,426 (67) 27,571 (72)
Emergency room 4203 (8) 1283 (3)
Outpatient 13,936 (25) 9722 (25)
Comorbidities diagnosed prior to the ulcer
Chronic obstructive  
pulmonary disease
4265 (8) 2878 (7)
Chronic alcoholism 4946 (9) 3605 (9)
Severe liver disease 911 (2) 559 (1)
Diabetes 4745 (9) 2936 (8)
Obesity 2660 (5) 1233 (3)
Cardiovascular disease 17,930 (33) 10,428 (27)
Endoscopies during the hospital contact for ulcers
Gastroscopy 38,834 (71) 28,815 (75)
Lower endoscopy1 3698 (7) 2256 (6)
Medication use in the year preceding the ulcer2
NSAIDs 12,378 (61) 6,793 (60)
PPI or H2- blockers 8916 (44) 4480 (40)
Eradication therapy3 2558 (13) 1751 (16)
NSAIDS, Aspirin and other nonsteroidal anti- inflammatory drugs.
1Specifically among patients diagnosed with colorectal cancer within 
the first year of follow- up, the prevalence of lower endoscopy was 49% 
within 3 months and 77% within 1 year.
2Use of medications in the year preceding peptic ulcer diagnosis was 
only available for patients diagnosed between 2005 and 2013.
3Combination of amoxicillin, clarithromycin, and metronidazole.
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ulcers were remarkably similar with respect to individual 
comorbid diseases, including a hospital- based history 
of chronic obstructive pulmonary disease and alcohol-
ism (Table 1). Recent use of NSAIDS and PPI or 
H2- blockers was frequent among both groups of ulcer 
patients, and every 6–7th patient had H. pylori- 
eradication therapy administered in the year preceding 
the diagnosis (Table 1).
Figure 1. Number of gastrointestinal cancers; 1–5- year absolute cancer risk (excluding cancer diagnosed during first year), treating death as a competing 
risk; and standardized incidence ratios (SIRs) of cancer one or more years after the first hospital contact for peptic ulcer, stratified by ulcer site.
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Gastrointestinal cancer in gastric and 
duodenal ulcer patients versus general 
population
During follow- up, a total of 1712 GI cancers were diag-
nosed among patients with gastric ulcers, and 1210 GI 
cancers among patients with duodenal ulcers. The absolute 
1–5- year risk of any GI cancer was 2.1% for patients with 
a gastric ulcer and 2.0% for patients with a duodenal 
ulcer. Site- specific cancer risks were similar in the two 
ulcer cohorts (Fig. 1). The SIR of any GI cancer compared 
with the general population was 1.38 (95% CI: 1.31–1.44) 
for patients with gastric ulcer and 1.30 (95% CI: 1.23–1.37) 
for patients with a duodenal ulcer (Fig. 1). Patients with 
gastric ulcer as a secondary registry diagnosis had a higher 
SIR than patients with gastric ulcer as the primary 
Table 2. Standardized incidence ratios (SIRs) (95% CIs) of cancer in patients with peptic ulcer disease, stratified by patient characteristics.
Gastric ulcer Duodenal ulcer
O/E SIR O/E SIR
All patients 1712/1243 1.38 (1.31–1.44) 1210/931 1.30 (1.23–1.37)
Women 780/600 1.30 (1.21–1.39) 440/350 1.26 (1.14–1.38)
Men 932/643 1.45 (1.35–1.55) 770/581 1.32 (1.23–1.42)
Age groups, years
0–<40 29/13 2.15 (1.44–3.09) 15/16 0.93 (0.52–1.53)
40–<65 659/431 1.53 (1.42–1.65) 578/370 1.56 (1.44–1.69)
65+ 1024/799 1.28 (1.20–1.36) 617/545 1.13 (1.05–1.23)
Calendar period, years
1994–1998 713/537 1.33 (1.23–1.43) 545/445 1.23 (1.12–1.33)
1999–2003 544/389 1.40 (1.28–1.52) 369/291 1.27 (1.14–1.41)
2004–2008 359/254 1.41 (1.27–1.57) 222/159 1.40 (1.22–1.60)
2009–2013 96/64 1.51 (1.22–1.84) 74/37 1.98 (1.56–2.49)
Type of ulcer diagnosis
Primary 1359/1013 1.34 (1.27–1.42) 1026/798 1.28 (1.21–1.37)
Secondary 353/231 1.53 (1.37–1.70) 184/133 1.39 (1.19–1.60)
Type of admission
Inpatient 1227/865 1.42 (1.34–1.50) 909/682 1.33 (1.25–1.42)
Emergency room 98/63 1.56 (1.27–1.90) 29/22 1.32 (0.88–1.90)
Outpatient 387/315 1.23 (1.11–1.36) 272/227 1.20 (1.06–1.35)
Chronic obstructive
Pulmonary disease
Yes 129/81 1.59 (1.33–1.89) 87/58 1.51 (1.21–1.86)
No 1583/1162 1.36 (1.30–1.43) 1123/874 1.29 (1.21–1.36)
Chronic alcoholism
Yes 216/67 3.25 (2.83–3.71) 174/50 3.47 (2.98–4.03)
No 1496/1177 1.27 (1.21–1.34) 1036/881 1.18 (1.11–1.25)
Severe liver disease
Yes 51/11 4.70 (3.50–6.18) 34/6 5.49 (3.80–7.67)
No 1661/1233 1.35 (1.28–1.41) 1176/925 1.27 (1.20–1.35)
Diabetes
Yes 145/92 1.58 (1.34–1.86) 87/16 1.43 (1.15–1.77)
No 1567/1152 1.36 (1.29–1.43) 1123/871 1.29 (1.22–1.37)
Obesity
Yes 56/42 1.33 (1.01–1.73) 35/23 1.55 (1.08–2.15)
No 1556/1201 1.38 (1.31–1.45) 1175/909 1.29 (1.22–1.37)
Cardiovascular disease
Yes 554/404 1.37 (1.26–1.49) 298/252 1.18 (1.05–1.33)
No 1158/839 1.38 (1.30–1.46) 912/679 1.34 (1.26–1.43)
Gastroscopy during same admission
Yes 1266/934 1.35 (1.28–1.43) 931/710 1.31 (1.23–1.40)
No 446/309 1.44 (1.31–1.58) 279/222 1.26 (1.12–1.42)
Lower endoscopy during same admission
Yes 109/86 1.26 (1.04–1.52) 80/57 1.41 (1.12–1.76)
No 1603/1157 1.39 (1.32–1.46) 1130/875 1.29 (1.22–1.37)
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diagnosis compared to the general population, whereas it 
was less clear if there was a difference for duodenal ulcer 
patients (Table 2). Among gastric ulcer patients, men had 
a higher SIR of cancer than women. SIRs of any GI cancer 
in this ulcer cohort versus the general population was 
higher in patients younger than 40 years than in patients 
aged 65 years or older. For duodenal ulcer patients, there 
was no gender difference in GI cancer risk, and only 
patients diagnosed with an ulcer at ages 40–<65 years had 
an excess risk of any GI cancer (Table 2). SIRs were similar 
regardless of whether or patients received a gastroscopic 
examination during the hospital contact for an ulcer.
Gastric cancer risk
Gastric ulcer patients had a higher occurrence of gastric 
cancer than duodenal ulcer patients, though absolute 1–5- 
year risks were 0.25% versus 0.19% and the SIRs compared 
to the general population were 1.92 (95% CI: 1.65–2.23) 
versus 1.38 (95% CI: 1.12–1.68) (Fig. 1), respectively. Both 
gastric and duodenal ulcers were more strongly associated 
with non- cardia gastric cancer than with cardia cancer (Fig. 1).
Risk of other gastrointestinal cancers
The absolute 1–5- year risks of other GI cancers among 
patients with gastric and duodenal ulcers were 1.9% and 
1.8%, with similar risks in the two cohorts for the indi-
vidual types of cancer. The highest absolute risk was 
observed for colon cancer, followed by oral and phar-
yngeal, gastric, pancreatic, liver, and rectal cancer, whereas 
risks of esophageal, small intestinal, anal, and gallbladder 
or biliary tract cancer were all <0.1%.
Although the overall SIR for other GI cancers was 
similarly increased for both gastric and duodenal ulcers 
(compared to the general population), there were some 
important differences by type of cancer. In general, the 
SIRs for smoking- and alcohol- related cancers (e.g., oral 
and pharyngeal, pancreatic, liver, and colon cancer) were 
higher for patients with gastric ulcers than duodenal ulcers. 
The SIR of esophageal squamous cell carcinoma was simi-
larly increased and more prominent than for adenocar-
cinoma, compared to the general population. The SIR of 
small intestinal cancer was higher among duodenal ulcer 
patients than gastric ulcer patients, whereas the SIR of 
gallbladder and biliary tract cancer was similarly increased 
in both cohorts. By contrast, one or more years after 
PUD diagnosis the SIRs for rectal cancer were decreased 
for both ulcer types. While patients with gastric ulcer 
had an increased risk of anal cancer, there was no asso-
ciation between duodenal ulcer and anal cancer (Fig. 1).
Subgroup analyses
Patients with chronic alcoholism or severe liver disease and 
gastric or duodenal ulcers were at greater increased risk 
of GI cancers than the general population. Ulcer patients 
with chronic obstructive pulmonary disease or diabetes also 
had slightly higher excess relative risks than patients without 
these diseases, compared with the general population 
(Table 2). PUD patients who redeemed a prescription for 
NSAIDs, aspirin, or antacids in the year preceding the ulcer 
diagnosis had a lower cancer risk than patients who did 
not use these drugs, compared to the risk in the general 
population (Table 3). In contrast, PUD patients who had 
been treated with eradication therapy seemed to have a 
higher cancer risk than patients who did not receive eradi-
cation therapy prior to their ulcer diagnosis (Table 3).
Direct comparison of cancer risk in patients 
with gastric and duodenal ulcer
When we directly compared the observed cancer risk 
among duodenal ulcer patients to the observed cancer 
risk in gastric ulcer patients as the reference group (Fig. 2), 
we found an 8% lower relative risk of GI cancer among 
the duodenal ulcer patients. The lower risk among duo-
denal compared to gastric ulcer patients stemmed primarily 
from an attenuated risk of oral and pharyngeal, gastric, 
liver, and rectal cancers. In contrast, duodenal ulcer patients 
had a higher risk of small intestinal cancer, and possibly 
a slightly higher risk of esophageal adenocarcinoma and 
gallbladder or biliary tract cancer compared with gastric 
ulcer patients (Fig. 2).
Discussion
In this nationwide cohort study of 93,141 persons with 
a hospital- based gastric or duodenal ulcer diagnosis, 
Table 3. Standardized incidence ratios (SIRs) (with 95% CIs) of cancer 
in patients with peptic ulcer disease diagnosed between 2005 and 
2013, stratified by medication use in the year preceding the ulcer 
diagnosis.
Gastric ulcer Duodenal ulcer
O/E SIR O/E SIR
NSAIDs
Yes 222/174 1.27 (1.11–1.45) 153/104 1.48 (1.25–1.73)
No 133/75 1.76 (1.48–2.09) 85/49 1.74 (1.39–2.16)
PPI or H2–blockers
Yes 123/104 1.19 (0.99–1.42) 82/57 1.44 (1.15–1.79)
No 232/146 1.59 (1.39–1.81) 156/96 1.63 (1.39–1.91)
Eradication therapy
Yes 41/29 1.40 (1.00–1.90) 42/23 1.86 (1.34–2.52)
No 314/220 1.42 (1.27–1.59) 196/130 1.51 (1.31–1.74)
Aspirin and other nonsteroidal anti- inflammatory drugs.
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we observed an increased risk of gastric cancer as well 
as other GI cancers one or more years after the ulcer 
diagnosis, compared with the general Danish popula-
tion. Site- specific absolute cancer risks were similarly 
low in both PUD cohorts, and the direction of the 
associations with both gastric and other GI cancers 
was consistent among patients with the two ulcer types. 
As we found that patients with duodenal ulcers (closely 
Figure 2. Standardized incidence ratios (SIRs) of cancer among duodenal ulcer patients compared to gastric ulcer patients.
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H. pylori- related) had a lower risk of several cancers 
than gastric ulcer patients, we question if H. pylori is 
an important player in the development of nongastric 
GI cancer.
H. pylori and its association with PUD and gastric 
cancer was discovered in the early 1980s [4]. In more 
recent years, epidemiological studies have focused on 
potential associations between the bacteria and other 
GI cancers [7–9], but also on diseases related to sys-
temic inflammation [26]. The associations between H. 
pylori and other GI cancers remains controversial [6], 
but speculation includes both direct and indirect effects 
of the organism [6, 26]. H. pylori infection may protect 
against esophageal adenocarcinoma through reduction 
in gastric acidity limiting precursor lesions in the lower 
esophagus [27, 28], but not squamous cell carcinoma 
[29, 30]. The association with gastric adenocarcinoma 
appears to be restricted to increased risk of noncardia 
cancer [31]. In contrast, H. pylori infection is associ-
ated with an increased risk of colorectal cancer [9, 
32–34]. Finally, evidence to support an association with 
other nongastric GI cancers is sparse, and null associa-
tions have been reported [8, 35–40]. In addition to H. 
pylori, several other environmental factors are associated 
with the risk of both PUD and cancer. Aspirin and 
other NSAIDs increase the risk of PUD but reduce the 
risk of gastric and colorectal cancer [11–13] (though 
such medications are likely discontinued at ulcer diag-
nosis). Use of proton- pump inhibitors have been identi-
fied as predictors of increased gastric cancer risk, 
potentially reflecting a causal association or confounding 
by indication [41]. Tobacco smoking is a common risk 
factor for both PUD [10, 16] and several GI cancers 
(oral, esophageal, gastric, pancreatic, and liver cancer) 
[14]. Cirrhosis, a strongly alcohol- related disease, 
also increases both risk of PUD [42] and GI cancer 
[14].
Based on the literature, we assumed that a higher 
proportion of duodenal than gastric ulcers would be H. 
pylori- related [2, 3]. Considering the proposed causal 
relation between H. pylori and cancer, we also expected 
to find a higher risk of various GI cancers (except for 
a lower risk of esophageal adenocarcinoma and gastric 
cardia cancer) among duodenal ulcer patients than among 
gastric ulcer patients. Instead, we found a lower risk of 
most cancers in patients with duodenal ulcers compared 
with gastric ulcers. The associations were not confined 
to patients with gastroscopically confirmed ulcer diagnoses. 
While the overall risk of esophageal cancer was increased 
in patients with duodenal ulcers, this stemmed mainly 
from an increased risk of squamous cell carcinoma, and 
we could not confirm a protective effect for adenocar-
cinoma in either of the cohorts. We confirmed that the 
increased risk of gastric cancer was mainly confined to 
noncardia cancer. However, whereas a previous study 
showed that duodenal ulcer was associated with decreased 
risk of gastric cancer [43], we found an increased risk 
for both gastric and duodenal ulcer patients. Our risk 
estimates for colon cancer were in agreement with studies 
reporting a modest increased risk of 20% [33]. The 
decreased risk of rectal cancer may reflect diagnosis of 
prevalent cancers during lower endoscopy following bleed-
ing among patients with ulcer disease (vs. no screening 
in the general population). Finally, we also noted that 
gastric ulcers conferred a higher risk than duodenal ulcers 
for GI cancers closely related to smoking and alcohol 
overuse.
Denmark is a welfare state with a tax- supported and 
uniformly organized healthcare system. We used nation-
wide data, including both hospitalized patients and 
patients diagnosed in the outpatient setting, making 
selection bias unlikely. As well, the diagnoses in the 
registries used in our study have high validity [20, 22] 
and the positive predictive value for PUD has been 
reported to be 85% [1]. We standardized on age, gender, 
and calendar year, but were unable to adjust for con-
founding factors. However, we found that the frequencies 
of covariates included in the analysis (coexisting mor-
bidities, proxy measures of lifestyle factors, and NSAID 
use) were balanced for patients with gastric and duodenal 
ulcers. Thus, in our second analysis, in which we com-
pared cancer risk among duodenal and gastric ulcer 
patients, the potential impact of confounding was 
reduced.
In conclusion, gastric and duodenal ulcers were asso-
ciated with an increased risk of gastric and other GI 
cancers compared with the general Danish population. 
We speculate that H. pylori may play a less critical 
role in the development of nongastric GI cancer than 
 previously hypothesized. Moreover, our findings may 
suggest that a follow- up gastroscopy for oro- pharyngeal, 
 esophageal, and gastric cancer could be clinically rel-
evant – at least among smokers. However, our data 
does not allow us to give recommendations on when 
such a repeat endoscopy should be performed; and 
finally to be cost- beneficial such follow- up procedure 
should also have a prognostic impact on the cancer 
survival.
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Appendix A1
Diagnosis codes (ICD- 8 and ICD- 10) 
used in the study
Cohort with ulcer disease
Gastric ulcer: ICD- 10: K25.
Duodenal ulcer: ICD- 10: K26.
Cancer
Gastrointestinal cancers, classified by ICD- 10: combined and 
separately: Oral and pharyngeal [tongue (C01- 02), oral cavity 
(C03- 06), salivary gland (C07- 08), pharyngeal tonsil/cavity 
(C09- 10), other parts of pharynx (C12- 13)], esophagus (C15): 
esophageal adenocarcinoma (C15 with morphology codes 
81403, 81433, 81443, 82113, 82303, 82603, 84303, 84803, 
84813, 84903) and squamous cell carcinoma (C15 with mor-
phology codes 80703 or 80713), gastric (C16): cardia C16.0 
and noncardia 16.1–16.6, small intestine (C17), colon including 
rectosigmoid (C18–19), rectum (C20), anal (C21), liver (C22), 
gallbladder and biliary tract (C23–24), and pancreas (C25).
Covariates
Chronic obstructive pulmonary disease
ICD- 8: 491, 492, ICD- 10: J41–J44.
Chronic alcoholism
ICD- 8: 291.00–291.99, 303.00–303.99, 571.09, 571.10, 
577.10, ICD–10: E24.4, E52.9A, F10.1, F10.2–10.9, G31.2, 
G62.1, G72.1, I42.6, K29.2, K.70, K85.2, K86.0, T50.0A, 
Z50.2, Z71.4, Z72.1.
Severe liver disease
ICD–8: 070.00, 070.02, 070.04, 070.06, 070.08, 573.00, 
456.00–456.09, ICD–10: B15.0, B16.0, B16.2, B19.0, K70.4, 
K72, K76.6, I85.
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Diabetes
ICD–8: 249.00- 249.09, 250.00- 250.09, ICD- 10: E10, E11, E14.
Obesity
ICD–8: 277.99, ICD–10: E65, E66.
Cardiovascular disease
ICD–8: 393–397, 400–404, 410–414, 424, 427.09–427.11, 
427.19, ICD–10: I05–08, I10–15, I20–25, I34–37, I39, I50, 
I51.1A.
Anatomical Therapeutic Chemical 
(ACT) codes used in the study
NSAIDs
Low- and high- dose aspirin (B01AC06, N02BA01, 
N02BA51); Selective cyclooxygenase- 2 inhibitors: 
M01AH01, M01AH02, M01AH03, M01AH05, M01AC05, 
M01AB05, M01AC06; other NSAIDs: All other codes within 
group M01A. Proton pump inhibitors (PPI): A02BC and 
Histamin2 receptor antagonist (H2RA): A02BA. H. pylori 
eradication (amoxicillin, clarithromycin, and metronida-
zole): J01CA04, J01FA09, and P01AB01.
